Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
ArQule
Information provided by (Responsible Party):
Daiichi Sankyo Inc.
ClinicalTrials.gov Identifier:
NCT01244191
First received: November 17, 2010
Last updated: April 15, 2016
Last verified: April 2016